Education
About Us
Working with TipRanks
Follow Us
Lonza Group Ltd (CH:LONN)
:LONN
LONN Stock Chart & Stats
Day’s Range― - ―
52-Week RangeCHF467.80 - CHF616.00
Previous CloseN/A
Volume30.07K
Average Volume (3M)203.62K
Market Cap
CHF38.62B
Enterprise ValueCHF43.18B
Total Cash (Recent Filing)CHF505.00M
Total Debt (Recent Filing)CHF3.78B
Price to Earnings (P/E)61.5
Beta1.23
Next Earnings
Jul 23, 2025EPS Estimate
7.06Next Dividend Ex-Date
May 13, 2025Dividend Yield0.73%
Share Statistics
EPS (TTM)9.13
Shares Outstanding72,226,180
10 Day Avg. Volume235,877
30 Day Avg. Volume203,615
Financial Highlights & Ratios
PEG Ratio24.63
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF666.21Price Target Upside21.31% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
---
Lonza Group Ltd News
PremiumCompany Announcements
Lonza Group AG Announces Cash Dividend for 2025
PremiumCompany Announcements
Lonza Group AG Announces Share Register Closure Ahead of AGM
PremiumCompany Announcements
Lonza Announces 2025 AGM and Publishes 2024 Reports---
Bulls Say, Bears Say
Bulls Say
Business ExpansionLeading biologics contract drug service provider expanding even more.
Financial PerformanceBetter profitability with a 7% EBITDA beat supported by a favorable product mix and strong operational performance in biologics.
Strategic FocusThe new 'One Lonza' strategy, focusing on Core CDMO and the strategic review concluding that CH&I no longer fits Lonza, is incrementally positive given the risks CH&I has posed on growth, margins, and returns over the past two years.
Bears Say
Financial ImpactThe financial impact of divesting Capsules could impact FCF more.
Market Share RiskLonza is at risk of losing market share to players that have better growth potential.
Segment WeaknessCapsules & Health Ingredients segment experienced a 13% EBITDA miss due to destocking in pharma capsules and negative pricing in nutraceuticals.
---
Options Prices
Currently, No data available
---
Ownership Overview
― Insiders
8.60%
Mutual Funds
<0.01% Other Institutional Investors
78.63% Public Companies and
Individual Investors
LONN FAQ
What was Lonza Group Ltd’s price range in the past 12 months?
Lonza Group Ltd lowest stock price was CHF467.80 and its highest was CHF616.00 in the past 12 months.
What is Lonza Group Ltd’s market cap?
Lonza Group Ltd’s market cap is CHF38.62B.
When is Lonza Group Ltd’s upcoming earnings report date?
Lonza Group Ltd’s upcoming earnings report date is Jul 23, 2025 which is in 91 days.
How were Lonza Group Ltd’s earnings last quarter?
Lonza Group Ltd released its earnings results on Jan 29, 2025. The company reported CHF7.98 earnings per share for the quarter, missing the consensus estimate of CHF7.987 by -CHF0.007.
Is Lonza Group Ltd overvalued?
According to Wall Street analysts Lonza Group Ltd’s price is currently Undervalued.
Does Lonza Group Ltd pay dividends?
Lonza Group Ltd pays a Semiannually dividend of CHF4 which represents an annual dividend yield of 0.73%. See more information on Lonza Group Ltd dividends here
What is Lonza Group Ltd’s EPS estimate?
Lonza Group Ltd’s EPS estimate is 7.06.
How many shares outstanding does Lonza Group Ltd have?
Lonza Group Ltd has 72,226,180 shares outstanding.
What happened to Lonza Group Ltd’s price movement after its last earnings report?
Lonza Group Ltd reported an EPS of CHF7.98 in its last earnings report, missing expectations of CHF7.987. Following the earnings report the stock price went down -2.624%.
Which hedge fund is a major shareholder of Lonza Group Ltd?
Currently, no hedge funds are holding shares in CH:LONN
---
Company Description
Lonza Group Ltd
Lonza Group Ltd supplies products and services to the pharmaceutical, biotech, and nutrition markets in Switzerland and internationally. It operates through Biologics, Small Molecules, Cell and Gene, and Capsules and Health Ingredients divisions. The Biologics division engages in the contract development and manufacturing services for biopharmaceuticals. The Small Molecules division operates as an integrated development and manufacturing service provider for small molecule drug substances and their intermediates. The Cell and Gene division develops technologies and platforms that industrialize the manufacturing processes and production of cell and gene therapies. It also offers contract development and manufacturing services for a range of allogeneic and autologous cell therapies, and exosome-based therapies, as well as viral vector gene therapies. This segment provides specialty raw materials and enabling technology solutions in cell and gene therapy, injectable drugs, vaccines, and bio-manufacturing markets. The Capsules and Health Ingredients division offers capsules, dosage form solutions, and health ingredients for pharmaceutical and nutraceutical customers. Lonza Group Ltd was founded in 1897 and is headquartered in Basel, Switzerland.
---
LONN Stock 12 Month Forecast
Average Price Target
CHF666.21
▲(21.31% Upside)
Technical Analysis
Novartis AG
―
Straumann Holding AG
―
Bachem Holding AG
―
Siegfried Holding AG
―
Sandoz Group Ltd
―
Best Analysts Covering LONN
1 Year
1 Year Success Rate
10/13 ratings generated profit
1 Year Average Return
+10.18%
reiterated a buy rating 8 days ago
Copying Charles Pitman CFA's trades and holding each position for 1 Year would result in 76.92% of your transactions generating a profit, with an average return of +10.18% per trade.
---